Molecular landscape of head and neck cancers – Therapeutic implications

INTRODUCTION

Head and neck squamous cell carcinoma (HNSCC) represents a biologically diverse group of tumors arising across multiple anatomic sites and influenced by etiologic agents such as tobacco, alcohol, betel nut, and high-risk human papillomavirus (HPV) infection. This heterogeneity is reflected in the genomic profiles of these tumors. Large-scale genomic efforts, including The Cancer Genome Atlas, have shown extensive somatic mutations, copy-number changes, chromosomal instability, and epigenetic alterations.^[1] These molecular differences account for variations in tumor morphology, clinical behavior, and therapeutic outcomes, complicating uniform treatment strategies. Despite the complexity, key dysregulated pathways converge on hallmark oncogenic processes such as altered cell-cycle control, enhanced proliferative signaling, survival, invasion, and metastatic progression.

EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) PATHWAY

EGFR, a receptor tyrosine kinase of the erythroblastic oncogene B (ErbB)/human epidermal growth factor receptor (HER) family, is frequently overexpressed in HNSCC despite the rarity of activating mutations or gene amplification. Tobacco exposure increases the release of EGFR ligands, enhancing tumor proliferation, angiogenesis, and invasion.^[2] On activation, EGFR stimulates multiple downstream signaling cascades, including the Janus kinase (JAK)–signal transducer and activator of transcription (STAT), phosphatidylinositol 3-kinase (PI3K)–Protein Kinase B (AKT)–mammalian target of rapamycin (mTOR), and rat sarcoma (RAS)– rapidly accelerated fibrosarcoma (RAF)– mitogen-activated protein kinase (MEK)– extracellular signal-regulated kinase (ERK) pathways.^[3] In addition to membrane signaling, EGFR can translocate to the nucleus and regulate transcription of genes, such as cyclooxygenase-2 (COX-2), cyclin D1, and inducible nitric oxide synthase (iNOS), contributing to resistance to therapy.^[4] Viral infection (e.g., Epstein–Barr virus [EBV]), radiation, and cetuximab exposure have been implicated in promoting nuclear EGFR localization.^[5]

THERAPEUTIC RELEVANCE

Cetuximab remains the only Food and Drug Administration (FDA)-approved EGFR-targeted agent for HNSCC. As monotherapy in recurrent or metastatic disease, cetuximab yields response rates near 13%.^[6] The EXTREME trial demonstrated that adding cetuximab to platinum-5-fluorouracil (5-FU) chemotherapy improved progression-free and overall survival.^[7] Panitumumab was evaluated in the SPECTRUM study, showing modest benefit primarily in p16-negative patients.^[8]

Nimotuzumab, when combined with chemoradiation, has shown survival advantages with favorable tolerability in large Indian studies.^[9]

EGFR tyrosine kinase inhibitors, such as gefitinib, erlotinib, afatinib, and dacomitinib, have been studied with variable success. Gefitinib did not outperform methotrexate in recurrent disease,^[10] while erlotinib achieved disease stabilization in heavily pre-treated patients.^[11] Irreversible inhibitors such as afatinib demonstrated improved progression-free survival (PFS) over methotrexate.^[12] Preclinical work suggests that afatinib may enhance the effects of pembrolizumab by increasing tumor antigenicity.^[13] Biomarkers such as caveolin-1 and sex determining region Y-box 2 (SOX-2) have been proposed to predict cetuximab response.^[14]

Acquired resistance to EGFR inhibitors typically emerges within months and is mediated by multiple mechanisms, including epithelial–mesenchymal transition (EMT) driven by the nerve growth factor (NGF)– tropomyosin receptor kinase A (TrkA) axis.^[15]

PI3K/AKT/mTOR PATHWAY

Aberrant PI3K signaling is one of the most prevalent molecular alterations in HNSCC, present in up to 90% of cases.^[16] PIK3CA mutations occur in approximately 16–25% of tumors and are more frequent in HPV-positive disease.^[17] PI3K pathway activation enhances survival, proliferation, and metabolic reprogramming and contributes to resistance against EGFR-targeted therapy.

THERAPEUTIC TARGETING

Single-agent PI3K inhibition has produced limited clinical activity. However, combining PI3K inhibitors with EGFR blockade may be beneficial in cetuximab-resistant disease.^[18] Agents such as alpelisib, buparlisib, and copanlisib remain under investigation, including a phase III trial of alpelisib plus paclitaxel. Resistance to PI3K inhibitors frequently involves compensatory mitogen-activated protein kinase (MAPK) pathway activation.^[19]

• AKT inhibitors such as perifosine and ipatasertib demonstrated minimal efficacy with substantial toxicities.^[20]

• mTOR inhibitors, including everolimus and temsirolimus, have shown limited benefit in recurrent or refractory HNSCC; baseline caspase-3 activity has been investigated as a predictive biomarker for temsirolimus.^[21]

MAPK PATHWAY

The RAS–RAF–MEK–ERK cascade promotes tumorigenesis, proliferation, and resistance to therapy. Dysregulation of this pathway is associated with poor prognosis in HNSCC.^[22]

JAK–STAT PATHWAY

Signal transducer and activator of transcription 3 (STAT3) activation drives immune evasion through upregulation of programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte–associated protein 4 (CTLA-4), suggesting that pathway inhibition may enhance responses to immunotherapy.^[23]

VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) PATHWAY

Overexpression of VEGF and activation of vascular endothelial growth factor receptor (VEGFR1)/2/3 promote angiogenesis, tumor survival, and dissemination. Sorafenib monotherapy has shown limited activity in refractory nasopharyngeal carcinoma, while combination with cisplatin and 5-FU demonstrated higher response rates.^[24] Bevacizumab combined with chemotherapy improved response rates but increased the risk of severe bleeding.^[25]

CDK4/6 PATHWAY

Alterations in cell-cycle regulators, particularly cyclin-dependent kinase inhibitor 2A (CDKN2A) and cyclin D1 (CCND1), are common in HPV-negative tumors, making CDK4/6 inhibition an appealing strategy. Preclinical evidence indicates that ribociclib may enhance radiosensitivity,^[26] though clinical benefit remains to be confirmed. HPV-positive tumors appear less responsive to CDK4/6 inhibition.^[27]

CELLULAR MESENCHYMAL–EPITHELIAL TRANSITION FACTOR (C-MET) PATHWAY

c-MET overexpression contributes to EGFR resistance. MET inhibitors have not demonstrated meaningful benefit in recurrent or refractory HNSCC, alone or in combination with cetuximab.^[28,29]

IMMUNOTHERAPY

HNSCC displays significant immunologic heterogeneity, with both immune-active and immune-exhausted phenotypes. This variability has implications for responsiveness to immune checkpoint inhibitors and highlights the need for predictive biomarkers.^[30]

CONCLUSION

Although molecular insights have expanded significantly over the past decade, therapeutic progress in recurrent or metastatic HNSCC remains modest. Understanding aberrant pathways, such as EGFR signaling, PI3K/AKT/mTOR, and VEGF, has prompted the development of targeted agents, but precision therapy remains in its early stages. Emerging targets, including Notch and CDK4/6 pathways, warrant further exploration. While cetuximab has an established role in treatment, pathway-specific targeted therapies are still evolving and require deeper integration into clinical decision-making.